These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 3100576)

  • 21. Enzyme replacement in a canine model of Hurler syndrome.
    Shull RM; Kakkis ED; McEntee MF; Kania SA; Jonas AJ; Neufeld EF
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12937-41. PubMed ID: 7809150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatic storage of glycosaminoglycans in feline and canine models of mucopolysaccharidoses I, VI, and VII.
    Haskins ME; Otis EJ; Hayden JE; Jezyk PF; Stramm L
    Vet Pathol; 1992 Mar; 29(2):112-9. PubMed ID: 1632054
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy in feline mucopolysaccharidosis I.
    Kakkis ED; Schuchman E; He X; Wan Q; Kania S; Wiemelt S; Hasson CW; O'Malley T; Weil MA; Aguirre GA; Brown DE; Haskins ME
    Mol Genet Metab; 2001 Mar; 72(3):199-208. PubMed ID: 11243725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I.
    Dierenfeld AD; McEntee MF; Vogler CA; Vite CH; Chen AH; Passage M; Le S; Shah S; Jens JK; Snella EM; Kline KL; Parkes JD; Ware WA; Moran LE; Fales-Williams AJ; Wengert JA; Whitley RD; Betts DM; Boal AM; Riedesel EA; Gross W; Ellinwood NM; Dickson PI
    Sci Transl Med; 2010 Dec; 2(60):60ra89. PubMed ID: 21123810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glycosaminoglycan storage in neuroanatomical regions of mucopolysaccharidosis I dogs following intrathecal recombinant human iduronidase.
    Chen A; Vogler C; McEntee M; Hanson S; Ellinwood NM; Jens J; Snella E; Passage M; Le S; Guerra C; Dickson P
    APMIS; 2011 Aug; 119(8):513-21. PubMed ID: 21749451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term outcome of Hurler syndrome following bone marrow transplantation.
    Whitley CB; Belani KG; Chang PN; Summers CG; Blazar BR; Tsai MY; Latchaw RE; Ramsay NK; Kersey JH
    Am J Med Genet; 1993 Apr; 46(2):209-18. PubMed ID: 8484412
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme replacement therapy in mucopolysaccharidosis type I.
    Miebach E
    Acta Paediatr Suppl; 2005 Mar; 94(447):58-60; discussion 57. PubMed ID: 15895714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I.
    Dickson PI; Ellinwood NM; Brown JR; Witt RG; Le SQ; Passage MB; Vera MU; Crawford BE
    Mol Genet Metab; 2012 May; 106(1):68-72. PubMed ID: 22402327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycosaminoglycan degradation fragments in mucopolysaccharidosis I.
    Fuller M; Meikle PJ; Hopwood JJ
    Glycobiology; 2004 May; 14(5):443-50. PubMed ID: 14718373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liver-Directed Human Amniotic Epithelial Cell Transplantation Improves Systemic Disease Phenotype in Hurler Syndrome Mouse Model.
    Rodriguez NS; Yanuaria L; Parducho KMR; Garcia IM; Varghese BA; Grubbs BH; Miki T
    Stem Cells Transl Med; 2017 Jul; 6(7):1583-1594. PubMed ID: 28585336
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of neuropathology in mucopolysaccharidosis I patients.
    Fuller M; Brooks DA; Evangelista M; Hein LK; Hopwood JJ; Meikle PJ
    Mol Genet Metab; 2005 Jan; 84(1):18-24. PubMed ID: 15639191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.
    Wraith JE
    J Inherit Metab Dis; 2001 Apr; 24(2):245-50. PubMed ID: 11405343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy.
    Traas AM; Wang P; Ma X; Tittiger M; Schaller L; O'donnell P; Sleeper MM; Vite C; Herati R; Aguirre GD; Haskins M; Ponder KP
    Mol Ther; 2007 Aug; 15(8):1423-31. PubMed ID: 17519893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A canine model of human alpha-L-iduronidase deficiency.
    Spellacy E; Shull RM; Constantopoulos G; Neufeld EF
    Proc Natl Acad Sci U S A; 1983 Oct; 80(19):6091-5. PubMed ID: 6412235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase).
    Wraith JE; Beck M; Lane R; van der Ploeg A; Shapiro E; Xue Y; Kakkis ED; Guffon N
    Pediatrics; 2007 Jul; 120(1):e37-46. PubMed ID: 17606547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations.
    Vite CH; Wang P; Patel RT; Walton RM; Walkley SU; Sellers RS; Ellinwood NM; Cheng AS; White JT; O'Neill CA; Haskins M
    Mol Genet Metab; 2011 Jul; 103(3):268-74. PubMed ID: 21482164
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glycosaminoglycan fragments as a measure of disease burden in the mucopolysaccharidosis type I mouse.
    Saville JT; McDermott BK; Fuller M
    Mol Genet Metab; 2018 Feb; 123(2):112-117. PubMed ID: 29273385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myoblast gene therapy in canine mucopolysaccharidosis. I: Abrogation by an immune response to alpha-L-iduronidase.
    Shull RM; Lu X; McEntee MF; Bright RM; Pepper KA; Kohn DB
    Hum Gene Ther; 1996 Aug; 7(13):1595-603. PubMed ID: 8864760
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Residual α-L-iduronidase activity in fibroblasts of mild to severe Mucopolysaccharidosis type I patients.
    Oussoren E; Keulemans J; van Diggelen OP; Oemardien LF; Timmermans RG; van der Ploeg AT; Ruijter GJ
    Mol Genet Metab; 2013 Aug; 109(4):377-81. PubMed ID: 23786846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mixed donor chimerism and low level iduronidase expression may be adequate for neurodevelopmental protection in Hurler Syndrome.
    Conway J; Dyack S; Crooks BN; Fernandez CV
    J Pediatr; 2005 Jul; 147(1):106-8. PubMed ID: 16027706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.